Multinational pharmaceutical company, Sanofi Healthcare announced on Wednesday that it has received authorisation from drug regulator Central Drugs Standard Control Organisation (CDSCO) for Qfitlia, a therapy used to prevent bleeding in haemophilia patients.
According to the statement released by the company, the approval from the regulator covers adults and adolescents aged 12 years and older, and older, with or without factor VIII or IX inhibitors.